CD69 Activators
CD69, also known as early activation antigen-1 (EA1), is a type II transmembrane protein that belongs to the C-type lectin family. It serves as an essential marker for early immune cell activation and is expressed on the surface of various immune cells, including T cells, B cells, natural killer (NK) cells, and neutrophils, upon activation. The primary function of CD69 is to regulate immune responses by mediating immune cell adhesion, migration, and cytokine production in response to antigenic stimulation. CD69 achieves these functions by interacting with its ligands, including lectins and other surface molecules, to modulate immune cell interactions and effector functions. Moreover, CD69 plays a crucial role in maintaining immune homeostasis and curbing excessive immune activation.
Activation of CD69 occurs through intricate signaling pathways triggered by antigenic stimulation or other immune stimuli. Upon activation, various signaling molecules, including protein kinase C (PKC) and mitogen-activated protein kinase (MAPK), are activated, leading to the rapid upregulation of CD69 expression on the surface of immune cells. Additionally, cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ) can induce CD69 expression through downstream signaling cascades. The activation of CD69 facilitates immune cell activation and the initiation of immune responses by promoting immune cell adhesion, migration to inflamed tissues, and cytokine production. Overall, the activation of CD69 is a critical step in the early immune response, highlighting its importance in orchestrating effective immune defense mechanisms against pathogens and foreign antigens.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII is a selective inhibitor of c-Jun N-terminal kinase (JNK). Indirectly, it activates CD69 by inhibiting JNK, a negative regulator of CD69 expression. The inhibition of JNK alleviates its suppressive effect on CD69, allowing for increased CD69 expression and subsequent activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinase (PI3K). Indirectly, it activates CD69 by inhibiting PI3K, a key signaling molecule in the PI3K/AKT pathway. Inhibition of PI3K disrupts downstream signaling cascades, relieving its inhibitory effect on CD69 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK). Indirectly, it activates CD69 by inhibiting JNK, a negative regulator of CD69 expression. The inhibition of JNK alleviates its suppressive effect on CD69, allowing for increased CD69 expression and subsequent activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK. Indirectly, it activates CD69 by inhibiting MEK, a crucial kinase in the MAPK pathway. Inhibition of MEK disrupts downstream signaling cascades, relieving its inhibitory effect on CD69 expression. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 is a selective ERK inhibitor. Indirectly, it activates CD69 by inhibiting ERK, a component of the MAPK pathway. Inhibition of ERK disrupts downstream signaling cascades, relieving its inhibitory effect on CD69 expression. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a selective MEK inhibitor. Indirectly, it activates CD69 by inhibiting MEK, a crucial kinase in the MAPK pathway. Inhibition of MEK disrupts downstream signaling cascades, relieving its inhibitory effect on CD69 expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-kappaB activation. Indirectly, it activates CD69 by inhibiting NF-kappaB, a transcription factor known to regulate CD69 expression. Inhibition of NF-kappaB disrupts downstream signaling cascades, relieving its inhibitory effect on CD69 expression. | ||||||
A-443654 | 552325-16-3 | sc-507339 | 1 mg | $140.00 | ||
A-443654 is a pan-Akt inhibitor. Indirectly, it activates CD69 by inhibiting Akt, a key component of the PI3K/AKT pathway. Inhibition of Akt disrupts downstream signaling cascades, relieving its inhibitory effect on CD69 expression. | ||||||